

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/863,976	05/23/2001	Farzan Rastinejad	PC10228B 1819		
7:	590 04/11/2003				
Paul H. Ginsburg Pfizer Inc 20th Floor			EXAMINER GOLDBERG, JEROME D		
11077 10111, 1111	10011 3130	*	1614		
		·	DATE MAILED: 04/11/2003	0	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applicatio	n No.	Applicant(s)				
		09/863,97	6	RASTINEJAD ET AL.				
	Office Action Summary	Examiner		Art Unit				
		Jerome D		1614				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
THE I - Externafter - If the - If NO - Failu - Any i	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. It is period for reply specified above is less than thirty (30) days, a reply of period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a). In no eve y within the statu will apply and will e, cause the appli	nt, however, may a reply be tim tory minimum of thirty (30) days expire SIX (6) MONTHS from to cation to become ABANDONED	ely filed will be considered timely. he mailing date of this communication. 0 (35 U.S.C. § 133).				
1)⊠	Responsive to communication(s) filed on <u>09 December 2002</u> .							
2a) <u></u> □	This action is FINAL . 2b) Th	nis action is	non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disp sition of Claims								
•	Claim(s) <u>26-56</u> is/are pending in the applicatio	on.						
•	4a) Of the above claim(s) is/are withdrawn from consideration.							
	☐ Claim(s) is/are allowed.							
	6)☐ Claim(s) is/are rejected.							
7)	_							
8)⊠ Claim(s) <u>26-56</u> are subject to restriction and/or election requirement.								
Applicati	on Papers							
9)[The specification is objected to by the Examine	er.						
10) 🔲 -	The drawing(s) filed on is/are: a)□ accep	pted or b)	objected to by the Exar	niner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
11)	The proposed drawing correction filed on			ved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action. 12) The oath or declaration is objected to by the Examiner.								
-	·	ammer.						
	under 35 U.S.C. §§ 119 and 120		4 25 II O O C 440/-)	(d) (6)				
_	Acknowledgment is made of a claim for foreign All b) Some * c) None of:	n priority und	ier 35 U.S.C. § 119(a)	-(a) or (t).				
a)(a haya haar	ropsiyod					
	 Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No. 							
	- La september 1 de la septemb							
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
) The translation of the foreign language pro Acknowledgment is made of a claim for domesti							
Attachmen		-						
2) 🔲 Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)			(PTO-413) Paper No(s) atent Application (PTO-152)				

Application/Control Number: 09/863,976

Art Unit: 1614

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

Restriction to one of the following invention is required under 35 U.S.C. 121.

Group I: claim(s) 26-55, drawn to a method for identifying organic non-peptide compounds useful in the treatment of cancer.

Group II: claim 56, drawn to a method of evaluating whether an organic compound can promote a wide-type activity in a mutant form of a mammali protein of the p. 53 family.

The several inventions above are independent and distinct, each from the other, as they have acquired a separate status in the art cancer as a separate subject matter for inventive effect and require independent searches. It is noted that the a reference to one Group I method would not be a reference to Group II method under 35 U.S.C. 103. Therefore, restriction for examination purposes is proper.

Applicant is required to make a provisional election even though this requirement is traversed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jerome D. Goldberg whose telephone number is (703) 308-4606. The examiner can normally be reached on Monday through Thursday from 9 AM to 3 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (703) 308-4725. The fax phone

Application/Control Number: 09/863,976

Art Unit: 1614

Page 3

numbers for the organization where this application or proceeding is assigned are (703) 308-4556 for regular communications and (703) 308-3592 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Goldberg/LR March 26, 2003

JEROME D. GOLDBERG